miRNA: licensed to kill the messenger.

miRNA: licensed to kill the messenger. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

miRNA: licensed to kill the messenger. Abstract Text:

Chandan K Sen,Sashwati Roy,

Current developments have brought non-coding genes under limelight together with their better-known siblings, the coding genes or mRNA. The 2006 Nobel Prize in Physiology or Medicine was awarded to Andrew Fire and Craig Mello for their 1998 discovery that double-stranded RNA triggers suppression of gene activity in a homology-dependent manner, a process named RNA interference (RNAi). Post-transcriptional regulation of genes was generally regarded as an odd regulatory mechanism for several years until it was learnt that regulatory trans-acting antisense RNAs exist in several species. Identification of a large number of small RNA molecules called microRNAs (miRNAs) elevated the overall field of biomedical RNAi to the striking level of current recognition. miRNAs represent a class of endogenous small ( approximately 22 nucleotides) RNA molecules that can repress protein synthesis. It is estimated that there are over 600 miRNAs in mammalian cells, and that about 30% of all genes are regulated by miRNA. Current understanding of the molecular mechanism of any disease would be incomplete without factoring in the functional significance of miRNA. In the category of the futuristic RNAi drugs, miRNA-based therapies are promising. The field has progressed rapidly as it relates to cancer research (highlighted in DNA and Cell Biology Volume 26, Number 4), while development in most other areas (highlighted in DNA and Cell Biology Volume 26, Number 3) of biomedical research remains in its infancy, offering significant opportunity for researchers. Approaches to interfere with miRNA function in vivo offer novel therapeutic opportunities. Lessons in gene therapy have taught us that tinkering with the genetic machinery comes with its own set of risks, especially in a clinical setting. miRNA-based therapies are also subject to such risks, which need to be prudently managed. Having acknowledged the potential risk, we have to recognize that new knowledge about the functional roles of miRNA is revolutionizing cell biology and will have a major impact on biomedical research imminently.

miRNA: licensed to kill the messenger. Publishing Authors By Initials

CK Sen,S Roy,

For similar genetic processes: gene expression regulation: epigenesis, genetic: gene silencing: rna interference research abstracts see: genetic processes: gene expression regulation: epigenesis, genetic: gene silencing: rna interference research

PUBMED ID PMID:

MEDLINE DATE:

miRNA: licensed to kill the messenger. Journal Published:

PUBLICATION TYPE: Review

Journal: DNA and cell biology

VOLUME: 26

Page Numbers: 193-4

Journal Abbreviation:

ISSN: 1044-5498

DAY: 3

MONTH: Apr

YEAR: 2007

miRNA: licensed to kill the messenger. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9004522

miRNA: licensed to kill the messenger. Keywords Mesh Terms:

KEYWORDS: RNA Interference

MESH TERMS: genetics

Chemical & Substance for Abstract: miRNA: licensed to kill the messenger. Information

Substance Name: MicroRNAs

Registry Number: 0

Grant and Affiliation Information for miRNA: licensed to kill the messenger.

AFFILIATION:

Country: United States

AGENCY: United States NINDS

GRANT: NS42617

ACRONYM: NS

MEDLINETA: DNA Cell Biol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

miRNA: licensed to kill the messenger Related Publications

• A novel range based QSAR study of human neuropeptide Y (NPY) Y5 receptor inhibitors.
• Assembly of feline calicivirus-like particle and its immunogenicity.
• Calotropis procera latex extract affords protection against inflammation and oxidative stress in Freund's complete adjuvant-induced monoarthritis in rats.
• Community eye health care for leprosy patients in west bengal, India.
• Comparative protein modeling and surface analysis of Leishmania sirtuin: A potential target for antileishmanial drug discovery.
• Development of primordial follicles in the hamster: role of estradiol-17beta.
• Effector proteins translocated by Legionella pneumophila: strength in numbers.
• Emotional distress in women presenting for breast imaging.
• Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism.
• Evaluation of the clinical decisions made for 2-year-olds referred for speech and language therapy: a follow-up study.
• Explosive Force Production and Fractionated Reaction Time in Elderly Low and High Active Women: 974: June 2 10:45 AM - 11:00 AM.
• Explosive force and fractionated reaction time in elderly low- and high-active women.
• Expression of G protein-coupled receptor 30 in the hamster ovary: differential regulation by gonadotropins and steroid hormones.
• Glossal angiomyoma: Imaging findings and endovascular treatment.
• Glycemic control in critically ill patients effect of delay in insulin administration.
• Harlequin fetus.
• Magnesium, essential for base excision repair enzymes, inhibits substrate binding of N-methylpurine-DNA glycosylase.
• Molecular mechanism of insulin resistance.
• Opposing functions of TFII-I spliced isoforms in growth factor-induced gene expression.
• Oxidative DNA damage repair in mammalian cells: a new perspective.
• Perceived hyperoxia: oxygen-induced remodeling of the reoxygenated heart.
• Profiles and correlates of aggressive behaviour among adults with intellectual disabilities.
• Six-year incidence of proteinuria in type 1 diabetic African Americans.
• Surface plasmon resonance as a time-resolved probe of structural changes in molecular films: considerations for correlating resonance shifts with adsorbate layer parameters.
• Survey of clinical engineering in developing countries and model for technology acquisition and diffusion.
• Technical aspects of online hemodiafiltration.
• Tocotrienols: the emerging face of natural vitamin E.
• Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine.
• Where people die: a multilevel approach to understanding influences on site of death in America.
• miRNA: licensed to kill the messenger.